

# ðŸ©¸ Hemophilia Prophylaxis Management System (ðŸ‡ºðŸ‡¸ ENGLISH VERSION)

A comprehensive clinical decision-support and cost analysis system implemented in Python.

This project was developed to simulate how the Social Security Institution (SSI) evaluates hemophilia patients for prophylaxis eligibility, calculates medication requirements, optimizes vial distribution, and performs large-scale statistical analysis. The system integrates medical rules, algorithmic optimization, cost modeling, and structured data aggregation.

---

## General Medical Background

### Hemophilia Disease
Clotting factors are proteins that play a critical role in blood coagulation. Deficiency of these factors results in bleeding disorders known as hemophilia.

The most common types:
* **Hemophilia A** â†’ Factor VIII deficiency
* **Hemophilia B** â†’ Factor IX deficiency

### Severity Classification
In healthy individuals, clotting factor levels range between 50% and 150%. Hemophilia severity is determined based on the factor level in the blood:

| Factor Level (%) | Severity |
| :--- | :--- |
| < 1 | Severe |
| â‰¥ 1 and â‰¤ 5 | Moderate |
| > 5 and < 50 | Mild |



### Treatment Principles
Patients receive medications either during bleeding episodes or as a preventive treatment (prophylaxis).

### Factor Effectiveness
* **1 IU/kg of Factor VIII** â†’ Increases blood level by approximately **2%**.
* **1 IU/kg of Factor IX** â†’ Increases blood level by approximately **1%**.

### Production Types & Pricing
* **Plasma-derived factor (P):** $0.30 per IU
* **Recombinant factor (R):** $0.40 per IU

### Inhibitor Presence
If the antibody level is **5 BU or higher**, the patient is considered inhibitor-positive. Inhibitor varlÄ±ÄŸÄ± ilacÄ±n etkinliÄŸini azaltÄ±r veya tamamen ortadan kaldÄ±rÄ±r.

---

##  Prophylaxis Rules

A patient is eligible for prophylaxis if they meet the following criteria:
1. **Severe** hemophilia **AND** inhibitor-negative.
2. **Moderate** hemophilia **AND** experienced an average of three or more bleeding episodes per month in the past year (**â‰¥ 36 total**) **AND** inhibitor-negative.

### Administration
* **Hemophilia A:** 3 times per week.
* **Hemophilia B:** 2 times per week.
* **Target Factor Level:** Each dose must raise the factor level to **40%**.

---

##  Dose Calculation Model

The minimum required dose per injection is calculated as follows:

`Minimum Dose (IU) = (Weight * (40 - Current Factor Level)) / Increase Factor`

**Increase Factor:**
* **2** for Factor VIII (Hemophilia A)
* **1** for Factor IX (Hemophilia B)

---

##  Vial Optimization Strategy

Available vial sizes: **2000, 1500, 1000, 500, 250 IU**.

The program applies a **greedy algorithm** (largest to smallest) to:
* Minimize vial count.
* Fully satisfy the dose requirement by rounding up to the nearest vial size.
* Avoid under-dosing.

The system calculates single-dose distribution, 4-week totals per patient, and global 4-week totals for all patients.

---

##  Cost Modeling

The system performs the following financial calculations:
* 4-week total medication cost.
* Annual cost (13 Ã— 4-week periods).
* Total SSI reimbursement amounts.
* Average annual medication amount per patient (IU).
* Average annual cost per patient ($).

---

##  Program Output

### For Each Patient
After data entry, the program provides a detailed summary:
* TR identification number and Name/Surname.
* Disease type (A/B) and Severity level.
* Prophylaxis eligibility status.
* **If eligible:** Factor type, weekly frequency, minimum required dose vs. actual dose, vial distribution (both single & 4-week), and total 4-week cost.

### Final Statistical Report
Once all data entry is complete, the system generates a global report:
* **Patient Distribution:** Total counts and percentages for A/B types and all severity levels.
* **Inhibitor Analysis:** Percentage of inhibitor presence (calculated separately for A and B).
* **Prophylaxis Analysis:** Percentage of patients on prophylaxis and targeted analysis for moderate cases.
* **Medication Usage:** Total IU for Factor VIII/IX (Plasma vs. Recombinant) and global 4-week/1-year costs.
* **Averages:** Global annual IU and cost averages per patient.
* **Maximum Value Tracking:** Identification of patients with the highest usage (IU) and highest cost ($).

---

##  Technical Design

The project demonstrates key software engineering and programming concepts:
* **Structured programming principles** and meaningful variable naming.
* **Mathematical dose computation** and greedy optimization logic.
* **Input validation** with strict constraints (e.g., weight, factor levels, data types).
* **Pure Python 3 implementation** using nested loops without relying on external libraries.

---



##  Academic Context
Course: Algorithms and Programming

Project Title: Hemophilia Prophylaxis Management System

Author: Yunus Can Duman

Institution: Ege University - Computer Engineering










# ðŸ©¸ Hemofili Profilaksi YÃ¶netim Sistemi (ðŸ‡¹ðŸ‡· TÃœRKÃ‡E VERSÄ°YON)

Bu proje, Sosyal GÃ¼venlik Kurumu'nun (SGK) hemofili hastalarÄ±nÄ± profilaksi (Ã¶nleyici tedavi) uygunluÄŸu aÃ§Ä±sÄ±ndan nasÄ±l deÄŸerlendirdiÄŸini simÃ¼le etmek, ilaÃ§ gereksinimlerini hesaplamak, flakon daÄŸÄ±tÄ±mÄ±nÄ± optimize etmek ve bÃ¼yÃ¼k Ã¶lÃ§ekli istatistiksel analizler yapmak amacÄ±yla Python dilinde geliÅŸtirilmiÅŸ bir klinik karar destek ve maliyet analiz sistemidir.

---

##  Genel TÄ±bbi Arka Plan

### Hemofili HastalÄ±ÄŸÄ±
PÄ±htÄ±laÅŸma faktÃ¶rleri, kanÄ±n pÄ±htÄ±laÅŸmasÄ±nda kritik rol oynayan proteinlerdir. Bu faktÃ¶rlerin eksikliÄŸi, hemofili olarak bilinen kanama bozukluklarÄ±na yol aÃ§ar.

**En yaygÄ±n tÃ¼rler:**
* **Hemofili A** â†’ FaktÃ¶r VIII eksikliÄŸi
* **Hemofili B** â†’ FaktÃ¶r IX eksikliÄŸi

### Åžiddet SÄ±nÄ±flandÄ±rmasÄ±
SaÄŸlÄ±klÄ± bireylerde pÄ±htÄ±laÅŸma faktÃ¶r seviyeleri %50 ile %150 arasÄ±ndadÄ±r. Hemofili ÅŸiddeti, kandaki faktÃ¶r dÃ¼zeyine gÃ¶re belirlenir:

| FaktÃ¶r Seviyesi (%) | Åžiddet |
| :--- | :--- |
| < 1 | AÄŸÄ±r (Severe) |
| â‰¥ 1 ve â‰¤ 5 | Orta (Moderate) |
| > 5 ve < 50 | Hafif (Mild) |



### FaktÃ¶r EtkinliÄŸi ve FiyatlandÄ±rma
* **FaktÃ¶r VIII (A):** 1 IU/kg doz, kan seviyesini **%2** artÄ±rÄ±r.
* **FaktÃ¶r IX (B):** 1 IU/kg doz, kan seviyesini **%1** artÄ±rÄ±r.
* **Plazma kaynaklÄ± faktÃ¶r (P):** 0.30 $ / IU
* **Rekombinant faktÃ¶r (R):** 0.40 $ / IU

---

##  Profilaksi KurallarÄ±

Bir hastanÄ±n profilaksiye (koruyucu tedavi) uygun sayÄ±lmasÄ± iÃ§in aÅŸaÄŸÄ±daki kriterleri karÅŸÄ±lamasÄ± gerekir:
1. **AÄŸÄ±r** hemofili **VE** inhibitÃ¶r negatif olmasÄ±.
2. **Orta** hemofili **VE** son bir yÄ±lda ayda ortalama en az 3 kanama ataÄŸÄ± (**toplam â‰¥ 36**) **VE** inhibitÃ¶r negatif olmasÄ±.

### Uygulama ÅžemasÄ±
* **Hemofili A:** Haftada 3 kez uygulama.
* **Hemofili B:** Haftada 2 kez uygulama.
* **Hedef:** Her doz, faktÃ¶r seviyesini **%40**'a yÃ¼kseltmelidir.

---

##  Doz ve Flakon Hesaplama

### Doz FormÃ¼lÃ¼
Enjeksiyon baÅŸÄ±na gereken minimum doz ÅŸu formÃ¼lle hesaplanÄ±r:

$$\text{Minimum Doz (IU)} = \frac{\text{AÄŸÄ±rlÄ±k} \times (40 - \text{Mevcut FaktÃ¶r Seviyesi})}{\text{ArtÄ±ÅŸ FaktÃ¶rÃ¼}}$$

### Flakon Optimizasyonu
Sistemde **2000, 1500, 1000, 500, 250 IU** boyutlarÄ±nda flakonlar tanÄ±mlÄ±dÄ±r. Program, **Greedy Algorithm** kullanarak:
* Toplam flakon sayÄ±sÄ±nÄ± minimize eder.
* Doz ihtiyacÄ±nÄ± tam karÅŸÄ±lamak iÃ§in her zaman bir Ã¼st flakon kombinasyonuna yuvarlar.
* Eksik doz riskini ortadan kaldÄ±rÄ±r.

---

##  Program Ã–zellikleri ve Ã‡Ä±ktÄ±lar

Program Ã§alÄ±ÅŸtÄ±rÄ±ldÄ±ÄŸÄ±nda iki aÅŸamalÄ± bir rapor sunar:

1.  **Bireysel Analiz:** Her hasta giriÅŸi sonrasÄ± TC No, hastalÄ±k tipi, ÅŸiddet seviyesi, profilaksi uygunluÄŸu ve uygunsa detaylÄ± ilaÃ§/maliyet dÃ¶kÃ¼mÃ¼.
2.  **Genel Ä°statistik Raporu:** Veri giriÅŸi bittiÄŸinde;
    * HastalÄ±k tipi ve ÅŸiddet daÄŸÄ±lÄ±mlarÄ± (yÃ¼zdesel).
    * Ä°nhibitÃ¶r prevalansÄ±.
    * Toplam ilaÃ§ tÃ¼ketimi (IU) ve maliyet analizi ($).
    * YÄ±llÄ±k SGK geri Ã¶deme projeksiyonlarÄ±.
    * En yÃ¼ksek maliyetli ve en yÃ¼ksek doz kullanan hasta takibi.

---

##  Teknik TasarÄ±m

* **Dil:** Pure Python 3
* **Algoritma:** Greedy Search (Flakon DaÄŸÄ±tÄ±mÄ± iÃ§in)
* **Veri YapÄ±larÄ±:** Dinamik listeler ve iÃ§ iÃ§e dÃ¶ngÃ¼ler.
* **GiriÅŸ KontrolÃ¼:** HatalÄ± veri giriÅŸini engelleyen validasyon mekanizmasÄ±.

---
##  Akademik BaÄŸlam

Ders: Algoritmalar ve Programlama

Proje BaÅŸlÄ±ÄŸÄ±: Hemofili Profilaksi YÃ¶netim Sistemi

Yazar: Yunus Can Duman

Kurum: Ege Ãœniversitesi - Bilgisayar MÃ¼hendisliÄŸi
